All Kubota Vision articles
-
ArticleNew myopia control trial results announced at IMC
EssilorLuxottica released an update on its clinical trial for its myopia management lens Essilor Stellest at the International Myopia Conference that took place in Rotterdam a few days ago. The three-year clinical trial, which was conducted together with the Wenzhou Medical University with over 200 children aged 8 to 13, ...
-
News briefs
Kubota Glass hits the U.S. market in New York
Manhattan Vision Associates (MVA) of New York will be the first eyecare shop to prescribe Kubota Vision’s myopia-management glasses in the U.S. As we have reported, the U.S. subsidiary of Kabuta Pharmaceutical Holdings registered its device with the U.S. Food and Drug Administration earlier this month. Registration with Taiwan’s Ministry ...
-
News briefs
Kubota Glass gets FDA registration
Kubota Vision, the U.S. subsidiary of Japanese-based Kubota Pharmaceutical Holdings, has announced that it has completed the registration with the Food and Drug Administration of its myopia management glasses. Called Kubota Glass, the device is based on the company’s proprietary technology, which consists in the projection of myopically-defocused virtual images ...
-
News briefs
Kubota gets ISO certification for myopia management device
Kubota Vision, a subsidiary of Kubota Pharmaceutical, has announced that it has received the Quality Management System - ISO 13485:2016 certification, an international safety and quality standard, for the design and development of ophthalmic medical devices. The company said it was in the final development stages of its Kubota Glass. ...
-
News briefs
Kubota Vision tests myopia-preventing smart glasses
Kubota Vision , the American subsidiary of the Japanese-based Kubota Pharmaceutical Holdings , last month enrolled its first patient for a clinical study aimed at controlling the development of myopia. Two months ago, the company reported positive results on a first research where myopically defocused images were projected by electronic ...
